Leo Pharma snaps up Astellas skin drugs for $723M; Citron exec admits short position in criticized Mallinckrodt;

@FiercePharma: GeneOne, Inovio's MERS vaccine enters PhI at Walter Reed. Story | Follow @FiercePharma

@EricPFierce: ICYMI: #Novo makes sure Denmark gets some of the action as it starts massive build up. More | Follow @EricPFierce

@CarlyHFierce: $GSK shoots for diabetes-esque platform approach with new respiratory med in hand. Article | Follow @CarlyHFierce

> Leo Pharma agreed to shell out €675 million ($723 million) for Astellas' global dermatology portfolio, including the eczema drug Protopic and other products for acne and skin infections. Release

> Citron Research chief Andrew Left said his firm has a short position in Mallinckrodt ($MNK), the drugmaker Citron criticized as "a worse offender" than Valeant in a tweet on Monday. Report

> AstraZeneca ($AZN) priced a $6 billion bond issue to fund its planned buyout of ZS Pharma ($ZSPH). Report

Medical Device News

@FierceMedDev: Medtronic reports strong leadless pacemaker data as it races St. Jude to FDA approval. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. Article | Follow @VarunSaxena2

@EmilyWFierce: Theranos and Safeway split after $350M deal, code-named "T-Rex," falls through. More from the WSJ | Follow @EmilyWFierce

> AliveCor adds former Google exec as CEO to further consumer ECG push. Articles

> Stanford engineers develop touch-free ultrasound device for tumor detection. More

Biotech News

@FierceBiotech: KIT team points pancreatic cancer therapy toward clinical trials. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Ex-Lumena gang pilots new course at Amplyx with antifungal R&D, $40.5M. Report | Follow @JohnCFierce

@DamianFierce: $HZNP "is threatening $ESRX's profiteering and exposing ... a lack of care for patients and respect for physicians." Release | Follow @DamianFierce

> Wave and Voyager keep the IPO train rolling, raising $172M in Wall Street debuts. More

> Boehringer slashes its R&D budget with a new focus on collaboration. Article

Biotech Research News

> MD Anderson group tracks 'modest' impact of lymphoma drug. Item

> Warp Drive Bio constructs a new cancer R&D tech platform. Story

> Microbiome study highlights bacterial strategy for treating severe diarrhea. News

> Case Western researchers spotlight role of rapid protein movement in hearing loss. More

> KIT team points pancreatic cancer therapy toward clinical trials. Article

Vaccines News

> GeneOne, Inovio's MERS vaccine enters PhI at Walter Reed. News

> MenAfriVac succeeds in sub-Saharan Africa, but the fight isn't over yet. More

> James Cook University researcher wins $2M Gates grant for malaria vaccine development. Story

> Novavax kicks off PhIII trial for its RSV vaccine. Article

> EMA safety review raises no issues with HPV vaccines from Merck, GSK. Report

Pharma Marketing News

> $1-per-pill alternative to Turing drug gets 'overwhelming' response: Imprimis CEO. Article

> Medivation's Xtandi sales force due for hiring, revamp as urology push falls flat. Report

> GSK shoots for diabetes-esque platform approach with new respiratory med in hand. More

> Allergan counting on January formulary boost to jump-start Namzaric launch. Story

> AstraZeneca holds on to purple Nexium trademark with early court win. Article

And Finally... More health systems are getting into the insurance business. Report

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."